GSK accused of market abuse

Suzie Neuwirth

FTSE 100-listed pharmaceuticals giant GlaxoSmithKline (GSK) has today been accused of undermining competition by the Office of Fair Trading.

The consumer watchdog said that the company had abused the market by paying three drug companies not to launch cheap copies of the antidepressant paroxetine, which GSK brands as Seroxat.

Alpharma, Generics UK and Norton Healthcare all received money not to enter the market with their copies of the drug.